Revvity Q2 FY26: where the revenue came from and where it went
The whole income statement of Revvity for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 6 – Jul 5, 2026
- Reported
- Aug 11, 2026
Revenue$0.73B
+1% year over year
Gross profit$0.42B
57% margin
Operating profit$0.09B
12% margin
Net profit$0.05B
7% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 0.73 | 100% | +1% |
| Life sciences | 0.36 | 49% | −1% |
| Diagnostics | 0.35 | 48% | −1% |
| Other | 0.02 | 3% | |
| Cost of revenue | −0.31 | 43% | |
| Gross profit | 0.42 | 57% margin | +3pp |
| R&D | −0.05 | 7% | −1pp |
| SG&A | −0.28 | 38% | +4pp |
| Operating profit | 0.09 | 12% margin | |
| Interest & other costs | −0.03 | ||
| Tax | −0.01 | ||
| Net profit | 0.05 | 7% margin | +0pp |
55 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest